Free Trial
NASDAQ:TCRT

Alaunos Therapeutics (TCRT) Stock Price, News & Analysis

Alaunos Therapeutics logo
$2.32 +0.19 (+8.92%)
(As of 11/21/2024 ET)

About Alaunos Therapeutics Stock (NASDAQ:TCRT)

Key Stats

Today's Range
$2.15
$2.34
50-Day Range
$1.98
$3.94
52-Week Range
$1.95
$32.85
Volume
14,680 shs
Average Volume
16,503 shs
Market Capitalization
$3.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

Receive TCRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alaunos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRT Stock News Headlines

Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?
Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?
See More Headlines

TCRT Stock Analysis - Frequently Asked Questions

Alaunos Therapeutics' stock was trading at $10.6050 at the start of the year. Since then, TCRT shares have decreased by 78.1% and is now trading at $2.32.
View the best growth stocks for 2024 here
.

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) released its quarterly earnings results on Tuesday, November, 14th. The company reported ($6.00) earnings per share for the quarter, missing the consensus estimate of ($4.50) by $1.50.

Alaunos Therapeutics's stock reverse split on Thursday, July 18th 2024. The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Alaunos Therapeutics' top institutional shareholders include MSD Partners L.P. (6.31%).
View institutional ownership trends
.

Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alaunos Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH), American Water Works (AWK) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
11/14/2023
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TCRT
Employees
40
Year Founded
N/A

Profitability

Net Income
$-35,140,000.00
Pretax Margin
-196,349.98%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.70 per share

Miscellaneous

Free Float
1,519,000
Market Cap
$3.71 million
Optionable
Optionable
Beta
-0.49
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:TCRT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners